Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology.
5-FU, 5-fluorouracil
CAD, coronary artery disease
CV, cardiovascular
CVD, cardiovascular disease
GDMT, guideline-directed medical therapy
GLS, global longitudinal strain
HER2 therapy
HER2, human epidermal growth factor receptor 2
HSCT, hematopoietic stem cell transplantation
ICI, immune checkpoint inhibitor
LVEF, left ventricular ejection fraction
VEGF, vascular endothelial growth factor
cardiomyopathy
diagnosis
immunotherapy
prevention
risk factor
risk prediction
screening
treatment planning
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
06
06
2022
revised:
22
07
2022
accepted:
27
07
2022
entrez:
10
10
2022
pubmed:
11
10
2022
medline:
11
10
2022
Statut:
epublish
Résumé
The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to grow as patients with cancer live longer as a result of lifesaving targeted and immunologic cancer therapies beyond the usual chemotherapy and/or radiation therapy. Often, potentially cardiotoxic anticancer treatment is necessary in patients with baseline cardiovascular disease. Moreover, patients may need to continue therapy in the setting of incident cancer therapy-associated cardiotoxicity. Herein, we present and discuss the concept of
Identifiants
pubmed: 36213359
doi: 10.1016/j.jaccao.2022.07.005
pii: S2666-0873(22)00321-0
pmc: PMC9537074
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
302-312Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Dr Dent is a consultant to and has received honoraria from AstraZeneca and Novartis. Dr Lenihan is a consultant (modest) to AstraZeneca, Bristol Myers Squibb, Myocardial Solutions, Clementia, Intellia, Bridge Bio, OncXerna, and SecuraBio. Dr Okwuosa is a consultant to Antev. Dr Porter has received an unrestricted grant from the Sally and Cloud Cray Family Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
Am J Case Rep. 2020 Aug 29;21:e924446
pubmed: 32860674
JAMA Cardiol. 2019 Oct 1;4(10):1007-1018
pubmed: 31433450
J Am Coll Cardiol. 2019 Dec 24;74(25):3153-3163
pubmed: 31856973
JACC Clin Electrophysiol. 2018 Dec;4(12):1491-1500
pubmed: 30573111
J Immunother Cancer. 2019 Nov 15;7(1):306
pubmed: 31730012
J Am Coll Cardiol. 2021 Feb 2;77(4):392-401
pubmed: 33220426
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
World J Surg Oncol. 2013 Nov 28;11:306
pubmed: 24283603
N Engl J Med. 2001 Mar 15;344(11):783-92
pubmed: 11248153
J Clin Oncol. 2011 Sep 1;29(25):3366-73
pubmed: 21768458
Cardiooncology. 2019 Jan 29;5:1
pubmed: 32154008
Cardiooncology. 2021 Jan 31;7(1):4
pubmed: 33517910
Cardiooncology. 2020 Nov 5;6(1):26
pubmed: 33292843
J Am Heart Assoc. 2020 Sep 15;9(18):e018403
pubmed: 32893704
Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e005984
pubmed: 32106704
PLoS One. 2022 Apr 7;17(4):e0265767
pubmed: 35390017
Clin Cancer Res. 2009 Oct 1;15(19):6250-7
pubmed: 19773379
J Am Heart Assoc. 2020 Jan 21;9(2):e013757
pubmed: 31960755
Oncol Rev. 2016 Nov 24;10(2):298
pubmed: 27994768
BMC Cancer. 2018 Apr 20;18(1):453
pubmed: 29678165
J Am Coll Cardiol. 2010 Jan 19;55(3):213-20
pubmed: 20117401
JACC CardioOncol. 2021 Mar;3(1):101-109
pubmed: 33817666
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
J Thromb Thrombolysis. 2021 May;51(4):846-853
pubmed: 32918669
Anticancer Res. 2007 Sep-Oct;27(5B):3465-70
pubmed: 17972502
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
BMC Pharmacol Toxicol. 2014 Sep 04;15:47
pubmed: 25186061
Eur Heart J. 2022 Jan 31;43(4):280-299
pubmed: 34904661
J Cancer Res Clin Oncol. 2019 Feb;145(2):511-521
pubmed: 30539281
JACC CardioOncol. 2019 Jul 17;1(1):1-10
pubmed: 34396157
Cardiooncology. 2020 Aug 08;6:14
pubmed: 32782828
J Am Acad Dermatol. 2020 Feb;82(2):311-316
pubmed: 31233857
N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
Clin Cancer Res. 2016 Feb 15;22(4):886-94
pubmed: 26446948
Breast Cancer Res Treat. 2016 Jun;157(3):535-44
pubmed: 27271767
Heart. 2018 Jun;104(12):971-977
pubmed: 29217634
Arterioscler Thromb Vasc Biol. 2020 Feb;40(2):301-308
pubmed: 31875699
Cardiovasc Diabetol. 2021 Jul 23;20(1):150
pubmed: 34301253
J Clin Oncol. 2015 Mar 1;33(7):773-81
pubmed: 25605840
PLoS One. 2014 May 06;9(5):e96736
pubmed: 24800827
JAMA Oncol. 2019 Sep 01;5(9):1310-1317
pubmed: 31169866
Fed Pract. 2019 May;36(Suppl 3):S18-S24
pubmed: 31138979
J Am Heart Assoc. 2018 Aug 7;7(15):e008637
pubmed: 30371238
Breast Cancer Res Treat. 2019 Jun;175(3):595-603
pubmed: 30852761
JAMA. 1994 Sep 28;272(12):957-62
pubmed: 8084064
J Card Fail. 2016 Jun;22(6):433-8
pubmed: 27079675
JACC CardioOncol. 2020 Dec 15;2(5):677-689
pubmed: 34396282
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Circ Genom Precis Med. 2021 Jun;14(3):e000082
pubmed: 33896190